Ziopharm Oncology (ZIOP) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BMO Capital Reiterates Bullish Take on ZIOPHARM (ZIOP) Following Meetings; Co. Considering Strategic Options as CAR-T Progresses
February 27, 2015 9:40 AM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $15 price target on ZIOPHARM Oncology (NASDAQ: ZIOP) following our discussion with management last night, to follow up on recent progress, and ongoing efforts to optimize value of its CAR-T collaboration with MD Anderson.
Birchenough noted that ZIOP acknowledged that it was in... More
